Contents
Download PDF
pdf Download XML
54 Views
12 Downloads
Share this article
Research Article | Volume 16 Issue 11 (November, 2026) | Pages 129 - 133
Study Of Microalbuminuria In Non-Diabetic Patients Of Acute Myocardial Infarction Presenting In A Tertiary Care Center A Crosssectional Study In Central India
 ,
1
Medical Officer, Department of Prosthodontics, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh
2
Associate Professor, Department of Prosthodontics, Bangladesh Dental College, Dhaka, Bangladesh.
Under a Creative Commons license
Open Access
Received
Oct. 15, 2026
Revised
Oct. 30, 2026
Accepted
Nov. 9, 2026
Published
Nov. 21, 2026
Abstract

Background: Microalbuminuria (MAU) reflects early endothelial dysfunction and is known to increase during acute myocardial infarction (AMI) due to ischemia–reperfusion injury and heightened inflammatory response. While its significance is well studied in diabetes, data in non-diabetic AMI patients remain limited. Hence, the present study was undertaken to evaluate the prevalence of MAU in non-diabetic AMI patients and to study its association with clinical variables. Methods: This hospital-based, cross-sectional observational study included 60 non-diabetic patients diagnosed with AMI, comprising 30 STEMI and 30 NSTEMI cases. Clinical history, cardiovascular risk factors, routine laboratory tests, cardiac biomarkers, ECG, and echocardiography were recorded. Early-morning spot urine samples were analyzed for albumin and creatinine, and UACR was calculated. Microalbuminuria was defined as UACR 30–300 mg/g. The primary outcome was prevalence of MAU; secondary outcomes included associations with age, gender, hypertension, dyslipidemia, and AMI type. Results: The mean age was 64.5±12.7 years, with equal male–female distribution. Microalbuminuria was detected in 75% of patients, with similar prevalence in STEMI (73.3%) and NSTEMI (76.7%) groups (p=0.766). MAU was slightly more frequent in hypertensives (80%) and dyslipidemics (80%), but these associations were not statistically significant. Lipid parameters and UACR levels were comparable across MAU-positive and -negative groups. No significant correlation was found between UACR and CK-MB levels (p=0.442). Conclusion: Microalbuminuria is highly prevalent in non-diabetic AMI patients, irrespective of demographic factors, risk profile, or infarct type. Its frequent occurrence highlights its potential as a simple, low-cost marker of systemic endothelial injury during AMI.

Keywords
INTRODUCTION

Acute Myocardial Infarction (AMI) remains a major global health concern and one of the leading causes of morbidity and mortality.1 It results from an imbalance between myocardial oxygen supply and demand, most often due to plaque rupture and thrombus formation, causing an abrupt reduction in coronary blood flow. AMI forms a part of the Acute Coronary Syndrome (ACS) spectrum, which includes Unstable Angina, non–ST Elevation Myocardial Infarction (NSTEMI), and ST Elevation Myocardial Infarction (STEMI).1,2

 

Although traditional cardiovascular risk factors such as diabetes, hypertension, dyslipidemia, and smoking are well known, newer biomarkers are gaining importance for early diagnosis and risk stratification. One such marker is microalbuminuria (MAU), defined as urinary albumin excretion of 30–300 mg/day or an albumin-to-creatinine ratio of 30–300 mg/g. Initially linked to diabetic nephropathy, MAU is now recognized as a marker of systemic endothelial dysfunction, vascular injury, inflammation, and oxidative stress—key mechanisms involved in AMI.3-5 During acute myocardial infarction, ischemia–reperfusion injury, elevated inflammatory cytokines (such as IL-6 and TNF-α), and oxidative stress increase glomerular permeability, resulting in transient or persistent microalbuminuria (MAU). As a marker of systemic endothelial dysfunction, MAU reflects overall vascular injury. Studies have shown that its presence in AMI patients is linked to poorer in-hospital outcomes, including recurrent ischemia, arrhythmias, heart failure, and higher mortality. Because MAU can be detected easily through a simple, non-invasive urine test, it may serve as a useful tool for early risk stratification.6-8

 

Although MAU has been widely studied in diabetic populations, limited data are available on its significance in non-diabetic AMI patients, especially those with hypertension. Since diabetes is a strong contributor to MAU, excluding diabetic patients helps clarify the true association between AMI and endothelial injury. Including hypertensive patients is appropriate, as hypertension is a major risk factor for AMI and independently contributes to endothelial dysfunction and microalbuminuria. Evaluating MAU in this subgroup may therefore provide important insight into its prognostic value in non-diabetic AMI patients.9 Given these considerations, the present study aims to assess the prevalence and significance of microalbuminuria in non-diabetic patients presenting with acute myocardial infarction, with the goal of determining its potential role as a simple, early marker of cardiovascular risk.

MATERIALS AND METHODS

After obtaining approval from the Institutional Ethics Committee, this hospital-based, cross-sectional observational study was conducted in the Intensive Care Unit (ICU) as well as the general medicine and cardiology wards of a tertiary care teaching hospital in Central India over a two-year period, from March 2023 to February 2025. A total of 60 patients were included through convenience sampling, comprising 30 cases of ST-elevation myocardial infarction (STEMI) and 30 cases of non-ST-elevation myocardial infarction (NSTEMI). The study population consisted of adult patients above 18 years of age admitted with a confirmed diagnosis of AMI, defined according to the Fourth Universal Definition of Myocardial Infarction (2018). Only non-diabetic patients were included. Diabetes mellitus was excluded through history and laboratory evaluation, including random blood sugar <200 mg/dL, fasting glucose <126 mg/dL, and HbA1c <6.5% on admission. Patients with chronic kidney disease, acute kidney injury, nephrotic syndrome, lupus nephritis, or urinary tract infection were excluded to avoid confounding due to pre-existing renal pathology.

 

Upon admission, each patient underwent a structured clinical assessment that included demographic details and detailed history of cardiovascular risk factors such as hypertension, dyslipidemia, smoking, and family history. A complete physical and systemic examination was performed. All participants underwent standard laboratory and imaging evaluation, including cardiac biomarkers (Troponin I/T, CK-MB), ECG, 2D echocardiography, complete hemogram, renal and liver function tests, and lipid profile. Glycemic tests were performed to confirm non-diabetic status. Urinary albumin measurement was performed using a single early-morning spot urine sample collected within the first 24 hours of admission. Samples were centrifuged, and the supernatant was stored at –20°C before analysis. Quantitative immunometric enzyme immunoassay (EIA) was used to measure urinary albumin, and the urine albumin-to-creatinine ratio (UACR) was calculated. Interpretation followed KDIGO and ADA guidelines: UACR <30 mg/g was considered normal, while 30–300 mg/g was categorized as microalbuminuria; patients with macroalbuminuria were excluded.

 

STEMI and NSTEMI were defined according to standard ECG criteria and elevated cardiac biomarkers. Microalbuminuria was defined as urinary albumin excretion between 30–300 mg/g creatinine. The primary outcome was to determine the prevalence of microalbuminuria in non-diabetic AMI patients. Secondary objectives included evaluating the association between microalbuminuria and variables such as age, gender, hypertension, lipid profile, and type of AMI (STEMI vs. NSTEMI).

 

Statistical Analysis

Data entries were performed using Microsoft Excel 2019, and statistical analysis was carried out using SPSS version 26. Categorical variables were expressed as frequencies and percentages and compared using the Chi-square test or Fisher’s exact test. Continuous variables were presented as mean ± standard deviation. The Shapiro–Wilk test was applied to assess normality. Depending on distribution, comparisons were made using either the independent t-test or the Mann–Whitney U test. Correlation between UACR and CK-MB was assessed using Spearman’s rho. A p-value <0.05 was considered statistically significant.

 

RESULTS

A total of 60 subjects were included in final analysis. The mean age of participants was 64.5±12.7 years. Patients without microalbuminuria had a median age of 65 years, while those with microalbuminuria had a median age of 63 years. The study included 30 males and 30 females. Only 5% were active smokers. Hypertension was present in 33.3% and was more common in patients with microalbuminuria. Dyslipidemia was observed in 25% of participants. STEMI and NSTEMI cases were equally distributed (50% each). Microalbuminuria was present in 75% of the study population, (Table 1).

 

Table 1: Baseline Characteristics of the Study Population(n=60)

Variable

Number (%)

Age (years)

64.5 ± 12.7

Men

30 (50.0%)

Women

30 (50.0%)

Smokers

03 (5.0%)

Hypertension

20 (33.3%)

Dyslipidemia

15 (25.0%)

STEMI

30 (50.0%)

NSTEMI

30 (50.0%)

Microalbuminuria Positive

45 (75.0%)

Microalbuminuria Negative

15 (25.0%)

 

Table 2 shows that microalbuminuria was more common in patients aged ≥60 years (72.2%) and in females (76.7%), though the differences were not statistically significant. Dyslipidemia was present in 25% of patients, with 80% of them showing microalbuminuria. Hypertension was seen in 33.3% of patients, and 80% of these, also had microalbuminuria. However, none of these associations reached statistical significance, (p>0.05).

 

 

Table 2: Demographic Characteristics and Comorbidities in Relation to Microalbuminuria Status

Variables

Microalbuminuria Negative n (%)

Microalbuminuria Positive n (%)

Total

n (%)

P value

Age Group (years)

<40

00 (0.0%)

02 (100.0%)

02 (3.3%)

0.168

40–60

05 (22.7%)

17 (77.3%)

22 (36.7%)

≥60

10 (27.8%)

26 (72.2%)

36 (60.0%)

Gender

Male

08 (26.7%)

22 (73.3%)

30 (50.0%)

1.000

Female

07 (23.3%)

23 (76.7%)

30 (50.0%)

Dyslipidemia

No

12 (26.7%)

33 (73.3%)

45 (75.0%)

0.863

Yes

03 (20.0%)

12 (80.0%)

15 (25.0%)

Hypertension

No

11 (27.5%)

29 (72.5%)

40 (66.7%)

0.752

Yes

04 (20.0%)

16 (80.0%)

20 (33.3%)

 

Comparison of lipid parameters showed no significant differences between patients with and without microalbuminuria. Total cholesterol levels were similar in both groups (199 ± 24.4 vs. 193 ± 25.1 mg/dL, p=0.411). Triglycerides were higher in the microalbuminuria group, but not significantly (177 ± 38.2 vs. 156 ± 40.2 mg/dL, p=0.075). LDL-C (121 ± 24.2 vs. 120 ± 20.9 mg/dL, p=0.980) and HDL-C levels (42.6 ± 7.79 vs. 41.4 ± 7.37 mg/dL, p=0.644) were also comparable, (Figure 1).

 

The mean UACR was similar between STEMI (136.78 ± 106.58 mg/g) and NSTEMI (138.06 ± 101.67 mg/g) groups, with no statistically significant difference (p=0.962), indicating comparable albumin excretion in both groups.

 

Microalbuminuria was present in 73.3% (22 out of 30) of the STEMI group and 76.7% (23 out of 30) of the NSTEMI group, with 75.0% (45 out of 60) of the total sample affected. The difference was not statistically significant (p=0.766), (Figure 2).

Spearman’s rank correlation analysis between urinary albumin-to-creatinine ratio (UACR) and CKMB levels showed a weak positive correlation (ρ = 0.101, p = 0.442), which was not statistically significant, (Table 3).

 

Table 3: Correlation between UACR and CK-MB

Variables Compared

Spearman’s rho (ρ)

df

p-value

UACR (mg/g) vs CKMB (ng/mL)

0.101

58

0.442

DISCUSSION

In the present study, microalbuminuria (MAU) was observed in 75% of non-diabetic patients with AMI, with almost identical prevalence in the STEMI (73.3%) and NSTEMI (76.7%) groups. The comparable prevalence in both infarct types suggests that MAU reflects a common pathophysiological mechanism, systemic endothelial dysfunction triggered by acute ischemia rather than the ECG pattern of infarction. Several studies have reported similar observations. Yassein RI et al10 documented MAU in 64% of non-diabetic ACS patients and found strong associations with adverse clinical events. Vigneshwaran et al11 reported a prevalence of 76% and highlighted correlations with impaired left ventricular function. Gamit D et al12 noted MAU in 65.8% of non-diabetic, non-hypertensive AMI cases, associating it with worse in-hospital outcomes. Basu A et al13 also demonstrated its prognostic value in AMI, particularly among younger patients and smokers. Collectively, these findings reinforce the high burden of MAU in AMI, independent of diabetes.

 

In the present study, age and gender did not significantly influence MAU prevalence. This contrasts with the study done by Yassein et al10 where they noted that increasing prevalence with age. The absence of demographic associations in our study suggests that the acute endothelial injury during AMI may overshadow baseline differences in vascular vulnerability. Likewise, no significant association was found between MAU and traditional cardiovascular risk factors such as hypertension, dyslipidemia, or smoking. Although hypertensive and dyslipidemic patients showed slightly higher MAU rates, the differences were not statistically significant. Similar findings were reported by Basu A et al13 and Mohamed P et al14, who also concluded that MAU behaves as an independent marker of acute vascular injury rather than being determined by baseline metabolic risk factors. Lipid parameters were comparable between MAU-positive and negative groups, similar to the findings of Vigneshwaran et al11, who reported high dyslipidemia prevalence with no direct correlation to MAU levels. The mean UACR values were also similar between STEMI and NSTEMI patients (136.8 vs. 138.1 mg/g), indicating that the extent of albuminuria is likely driven by systemic inflammation and hemodynamic stress rather than infarct type. Prior work by Lazzer C et al15 supports this, highlighting that MAU correlates more strongly with inflammatory burden than with the clinical subtype of MI.

 

Existing literature consistently demonstrates the prognostic significance of MAU in AMI. Lekatsas I et al16 reported higher rates of pulmonary edema, arrhythmias, and mortality among MAU-positive patients. In the Indian context, Sathisha et al17 and Giri S et al18 also documented increased adverse events among patients with elevated urinary albumin. Although our study could not evaluate long-term outcomes, the high prevalence of MAU supports its role as a sensitive marker of endothelial dysfunction during AMI. Differences between our results and those of studies that found stronger associations with hypertension, smoking, or dyslipidemia (Al-Saffar et al19; Paudel N et al20) may be attributed to variations in population characteristics, sample sizes, and inclusion criteria. Nevertheless, the overall evidence consistently points toward the utility of MAU as a marker of vascular injury and heightened cardiovascular risk.

 

The implications of our findings are clinically relevant. Microalbuminuria is inexpensive to measure, requires only a spot urine sample, and can be easily incorporated into routine AMI evaluation. Its presence may help identify patients at higher risk of complications, supporting more intensive monitoring and aggressive secondary prevention strategies. Incorporation of MAU into existing risk scores may also enhance prognostic accuracy, especially in resource-limited settings. Future research should focus on larger, multi-center prospective studies with long-term follow-up to clarify the prognostic role of MAU and evaluate whether interventions aimed at reducing albuminuria can influence outcomes. Despite sincere efforts, the present study has certain limitations. The sample size was relatively small, which may limit the generalizability of the findings. Additionally, the study was conducted at a single centre, restricting the diversity of the study population. As the research was carried out in a tertiary care hospital, the possibility of hospital-based bias cannot be completely ruled out.

CONCLUSION

The present study shows that microalbuminuria is highly prevalent in non-diabetic AMI patients, independent of age, sex, risk-factor profile, or infarct type. Despite not distinguishing STEMI from NSTEMI, its frequent occurrence highlights its potential utility as a simple and effective biomarker of systemic endothelial injury during AMI. Given its simplicity, low cost, and strong association with adverse cardiovascular outcomes reported in earlier studies, routine assessment of microalbuminuria may strengthen early risk stratification and guide timely therapeutic decisions in AMI, particularly in resource-limited settings.

REFERENCES

1.       Antman EM, Braun Wald E Braunwald. Heart disease. A textbook of cardiovascular medicine. 6th Edn. Philadelphia; WB Saunders 2001.

2.       Fabijanic D, Culic V, Bozic I, et al. Gender difference in in-hospital mortality and mechanisms of death after the first acute myocardial infarction. Ann Saudi Med 2006; 26:455-460.

3.       de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol. 2006 Aug;17(8):2100-5.

4.       American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28(Suppl 1): S4- S36. 

5.       Yuyun M F, Adler A I, Wareham N J. What is the evidence that microalbuminuria is a predictor of cardiovascular disease events? Curr Opin Nephrol Hypertens. 2005; 14:271-6. 

6.       Francisco J, Del Re DP. Inflammation in Myocardial Ischemia/Reperfusion Injury: Underlying Mechanisms and Therapeutic Potential. Antioxidants (Basel). 2023 Oct 31;12(11):1944.

7.       Haffner SM, Stern MP, Gruber MK, Hazuda HP, Mitchell BD, Patterson JK. Microalbuminuria. Potential marker for increased cardiovascular risk factors in non-diabetic subjects? Arteriosclerosis 1990; 10:727–31. 

8.       Cirillo M, Senigalliesi L, Laurenzi M, Alfieri R, Stamler J, Stamler R, et al. microalbuminuria in non-diabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study. Arch. Intern. Med. 1998; 158:1933-9. 

9.       Al-Saffar HB, Nassir H, Mitchell A, Philipp S. Microalbuminuria in non-diabetic patients with unstable angina/non ST-segment elevation myocardial infarction. BMC Res Notes. 2015 Aug 25;8:371.

10.    Yassein RI, Mena MB, Shazly MS, et al. Microalbuminuria in non-diabetic patients with acute coronary syndrome. J Cardiovasc Dis. 2022;13(4):447-453.

11.    Vigneshwaran M, Grashia T, Thomas Kingsley C, Suresh Kumar P. To evaluate the relationship between microalbuminuria and acute myocardial infarction in non-diabetic, non-hypertensive patients.  Int J Acad Med Pharm. 2023; 5 (2); 368-371

12.    Gamit D, Vanani B, Patel C, Mishra A, Patel A, Evaluation of microalbuminuria in non-diabetic and non-hypertensive patients with acute myocardial infarction. Int J Clin Biochem Res 2017;4(3):225-228

13.    Basu A, Jhala JS. Association of microalbuminuria in non-diabetic and non-hypertensive patients with myocardial infarction. Int J Adv Med 2015;2:196-200.

14.    Mohamed P, Lorenz T, Bagialakshmi G. A study on association of microalbuminuria in nondiabetic and non-hypertensive patients with acute myocardial infarction. J. Evid. Based Med. Healthc. 2019; 6(2): 82-86.

15.    Lazzeri C, Valente S, Chiostri M, Picariello C, Attana P, Gensini GF. Microalbuminuria in non-diabetic stemi: An independent predictor for acute kidney injury. Scandinavian Cardiovascular Journal. 2012 Jul 10;46(6):324–9.

16.    Lekatsas I, Koulouris S, Triantafyllou K, Chrisanthopoulou G, Moutsatsou-Ladikou P, Ioannidis G, et al. Prognostic significance of microalbuminuria in nondiabetic patients with acute myocardial infarction. Int J Cardiol. 2006;106(2):218-223.

17.    Sathisha TG, Goud M, Avinash SS, Shetty JK, Oinam D, Devaki RN. Microalbuminuria in nondiabetic, non-hypertensive myocardial infarction patients and its relation to lipid profile and cardiac markers. J Clin Diagn Res. 2011;5(6):1158-1160.

18.    Giri S, Mohanty N. Prognostic implications of microalbuminuria in nondiabetic, non-hypertensive patients with acute coronary syndrome. Glob J Res Anal. 2017;6(4):75-78.

19.    Al-Saffar HB, Nassir H, Mitchell A, Philipp S. Microalbuminuria in non-diabetic patients with unstable angina/non-ST segment elevation myocardial infarction. BMC Res Notes. 2015;8:371.

20.    Paudel N, Maskey A, Karki D, et al. Profile of Non-Diabetic patients with Microalbuminuria in Acute Coronary Syndrome: A hospital based study. Nepalese Heart Journal 2019; Vol 16 (2): 63-67.

 

Recommended Articles
Research Article
Hemodynamic Stability Following Induction with Etomidate versus Thiopentone Sodium in Controlled Hypertensive Patients Undergoing Elective Surgery: A Prospective Randomized Study
...
Published: 20/11/2026
Download PDF
Review Article
Circulating Biomarkers of Mitochondrial Dysfunction and Oxidative Stress in Premature Coronary Artery Disease: Association with Endothelial Dysfunction and Clinical Disease Severity—A Systematic Review and Meta-analysis
...
Published: 20/11/2026
Download PDF
Research Article
Early Outcomes Of Total Arterial Coronary Artery Bypass Grafting: A Retrospective Institutional Analysis
...
Published: 19/11/2026
Download PDF
Research Article
Comparative Evaluation of Cognitive Function in Patients with Schizophrenia Versus Bipolar Disorder: A Cross-Sectional Study
Published: 14/04/2024
Download PDF
Chat on WhatsApp
Copyright © EJCM Publisher. All Rights Reserved.